Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06, Zacks reports. During the same quarter last year, the firm posted ($0.24) earnings per share.
Acurx Pharmaceuticals Stock Down 2.7 %
ACXP opened at $1.77 on Friday. The firm has a market cap of $28.76 million, a price-to-earnings ratio of -1.62 and a beta of -1.73. Acurx Pharmaceuticals has a 52 week low of $1.52 and a 52 week high of $5.28. The business’s 50 day moving average is $1.96 and its two-hundred day moving average is $2.14.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research note on Thursday.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Featured Stories
- Five stocks we like better than Acurx Pharmaceuticals
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks Near 52-Week Lows That Could Be Top Buys Right Now
- How to Effectively Use the MarketBeat Ratings Screener
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Bank Stocks – Best Bank Stocks to Invest In
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
